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Abstract
Background: New blood vessel formation, or angiogenic switch, is an essential event in the development of solid
tumors and their metastatic growth. Tumor blood vessel formation and remodeling is a complex and multi-step
processes. The differentiation and recruitment of mural cells including vascular smooth muscle cells and pericytes
are essential steps in tumor angiogenesis. However, the role of tumor cells in differentiation and recruitment of
mural cells has not yet been fully elucidated. This study focuses on the role of human tumor cells in governing the
differentiation of mouse mesenchymal stem cells (MSCs) to pericytes and their recruitment in the tumor
angiogenesis process.
Results: We show that C3H/10T1/2 mouse embryonic mesenchymal stem cells, under the influence of different
tumor cell-derived conditioned media, differentiate into mature pericytes. These differentiated pericytes, in turn, are
recruited to bind with capillary-like networks formed by endothelial cells on the matrigel under in vitro conditions
and recruited to bind with blood vessels on gel-foam under in vivo conditions. The degree of recruitment of
pericytes into in vitro neo-angiogenesis is tumor cell phenotype specific. Interestingly, invasive cells recruit less
pericytes as compared to non-invasive cells. We identified tumor cell-secreted platelet-derived growth factor-B
(PDGF-B) as a crucial factor controlling the differentiation and recruitment processes through an interaction with
neuropilin-1 (NRP-1) in mesenchymal stem cells.
Conclusion: These new insights into the roles of tumor cell-secreted PDGF-B-NRP-1 signaling in MSCs-fate
determination may help to develop new antiangiogenic strategies to prevent the tumor growth and metastasis
and result in more effective cancer therapies.
Background
Tumor cells assign neighboring blood vessels to support
their own blood supply for oxygen and nutrients and
finally for intravasation (to enter into the blood vessels)
and extravasation (metastatic spread) through promoting
pathologic neovascularization/angiogenesis [1-3]. This
event is potentiated by tumor cells through the produc-
tion of diffusible angiogenic factors [4-6]. New blood
vessel formation/angiogenesis and remodeling of the
vessel is a complex event and is dependent on prolifera-
tion, differentiation, mobilization and attachment of
endothelial cells (ECs) and mural cells (MCs) with dif-
ferent phenotypic variants such vascular smooth muscle
cells (VSMCs) and pericytes (PCs) in an autocrine-para-
c r i n em a n n e r[ 7 - 1 1 ] .T h el i t e r a t u r eo nt h em o l e c u l a r
interactions of tumor cells with ECs for the angiogenic
switch is appreciable, but less is known about mural
cells.
VSMCs/PCs, which are located in different vascular
systems according to their needs [11], play critical roles
in both normal and pathologic vascular development,
integrity and its maintenance [11-14]. Although VSMCs
and PCs are morphologically similar, and express com-
mon molecular markers, they may function differently
[11]. The vascular SMCs provide structural support to
the large vessels and are critical regulators of blood
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any medium, provided the original work is properly cited.flow, while PCs appear to be involved in the early events
of capillary sprouting. The PCs are regularly found lying
at and in front of the advancing tips of endothelial
s p r o u t sa n dm a ys e r v ea sag u i d i n gs t r u c t u r eo f
endothelial outgrowth [11,12] and termination of the
event [13]. PCs are irregular in shape in tumors and
loosely associated with ECs on tumor vessels [15,16],
During new blood vessel formation and assembly,
recruitment of PCs through the differentiation of pre-
cursor cells (mesenchymal), migration and attachment
to the newly formed capillaries are vital events of this
multistep process [17,18]. However, the role(s) of tumor
cells in differentiation, recruitments and attachment of
these cells are still under described. Therefore, we are
interested to explore whether the tumor cells have the
ability to differentiate, recruit and interact with PCs to
establish new blood vessels for their maintenance.
Accumulated evidences have shown that both endothe-
lial and non-endothelial cells recruit pericytes in tumor
blood vessels through PDGF-B, its receptor (PDGF-Rb)
and VEGF signaling networks in a mouse fibrosarcoma
model and in U87MG glioma model [18,19]. Recently,
our studies have found that breast tumor cells are cap-
able of modulating the migration of vascular SMCs in
vitro, and this event is mediated through vascular
endothelial growth factor (VEGF)/B-form of platelet-
derivative growth factor (PDGF-B) - neuropilin-1 (NRP-
1) signaling pathways [20,21]. This study, for the first
time to our knowledge, shed light on the molecular inter-
actions of tumor cells with mesenchymal stem cells, and
offers new opportunities to improve the understanding of
the regulation of pathologic pericytes by cell-cell interac-
tions through successive studies. The main objective of
the present work is to extend our initial findings and test
the hypothesis that the interaction of tumor cells with
mural precursor cells may cause differentiation of precur-
sor cells to PCs (mesenchymal to pericyte transition) and
the recruitment/attachment for tumor angiogenesis.
To test this concept, we determined whether different
tumor cell-derived conditioned media are able to differ-
entiate and recruit the mesenchymal stem cells to peri-
cytes. We demonstrate that the tumor cell-derived
conditioned media are capable of differentiating the
stem cells to PCs; ultimately recruiting them to bind
with endothelial cells differentially. The studies also
reveal that tumor cell-secreted PDGF is the responsible
molecule for differentiation as well as for recruitment
through a physical interaction with NRP-1.
Results
Tumor cell-derived conditioned media (TCM) enhance the
proliferation of mesenchymal stem cells
For new blood vessel formation, mesenchymal stem cells
need to proliferate. In this experiment, we determined
whether tumor cell-derived diffusible factors in the con-
ditioned media are able to increase the mesenchymal
stem cell’s proliferation rate. To test this, C3H/10T1/2
mouse mesenchymal stem cells were used for this study.
These cells were isolated from C3 H mouse embryo
pluripotent stem cells and considered as mesenchymal
cells because they have the ability to differentiate into a
variety of mesodermal cell lineages [22]. Our studies are
in agreement with previous findings and indicate that
this embryonic cell line is the mesenchymal type. The
immuno-Western blot analysis showed that epithelial
marker proteins (i.e., E-Cadherin, Keratin 19, Beta-cate-
nin) are absent in these cells while mesenchymal mar-
ker, vimentin, is overexpressed (Fig. 1A). Moreover,
mural cell markers are either absent or minimally
expressed in 10T1/2 cells (Fig. 1B and 1C). These
include a-SMA, calponin and desmin. After confirma-
tion of the stem cell behavior, 10T1/2 cells (60% conflu-
ent) were incubated with different TCM for 24 hours.
Cells were trypsinized and stained with trypan blue for
the count in Cellometer Auto T4 (Nexcelom Bioscience,
Lawrence, MA 01843). We found that the cell number
of the conditioned media incubated 10T1/2 cells
increased more significantly than the control, and maxi-
mum cell number was increased in the invasive (MDA-
MB-231 and PaCa-2) cell line-derived-CM in compari-
son to the non-invasive (MCF-7) cell line-derived CM
(Fig. 1D). In order to confirm whether the induction of
cell number was due to the proliferation or inhibition of
apoptosis, we determined the apoptosis using cell death
ELISA assay. No significant apoptotic cell death was
observed in TCM exposed and unexposed cells (data
not shown). Collectively, these studies indicate that
TCM induced induction of cell numbers is due to the
stimulation of cellular proliferation.
TCM is able to differentiate the mesenchymal stem cells
to pericytes
The communication between tumor cells and surround-
ing stroma is a well established phenomenon and this
event is very crucial for tumor growth [23-26]. However,
tumor cell-induced mesenchymal stem cell (MSC) tran-
sition to pericytes and their attachment in contribution
to neovascularization has not yet been fully elucidated.
Therefore, we investigated whether human tumor cells
are able to force the mouse MSC to differentiate to peri-
cytes (PCs). To do so, semi-confluent 10T1/2 MSC were
incubated with 10T1/2 media (RM), or different tumor
cell (MIA-PaCa-2, MCF-7 and MDA-MB-231)-derived
conditioned media (TCM) for 24 and 72 h and fixed
and processed for immunofluroscent staining with alpha
smooth muscle actin (a- S M A ) ,ap o s i t i v em a r k e ro f
mural cells [11]. As shown in Fig. 2, a-SMA antibody
weakly immuno-reacts with RM-exposed cells as
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reactions were increased in time dependent fashion.
Furthermore, we found that the staining intensity of a-
SMA was reliant on the aggressiveness of the tumor
cells. For example, MCF-7 non-invasive breast tumor
cell-derived CM moderately enhanced a-SMA expres-
sion in 10T1/2 cells, while its expression was very
strong in invasive cells (MDA-MB-231 and MIA PaCa-
2)-derived CM treated cells. The numbers of a-SMA
positive cells increased significantly in TCM-exposed
cells as compared to RM-exposed cells (data not
shown). The morphology of the 10T1/2 cells in the
TCM groups was markedly altered to pericytes-like cells
that exhibited a slender, bipolar morphology with cellu-
lar processes.
To confirm the immunofluorescence staining results,
we have determined the status of the aSM-actin and
desmin protein level in 10T1/2 cells following incuba-
tion with different cell-derived conditioned media for 24
h. We found significant induction of aSM-actin and
desmin expression in TCM exposed cells as compared
to RM (Fig. 2C).
PDGF-B induces Mesenchymal-Pericyte-Transition (MPT)
It is well established that tumor cells secrete different
kinds of growth factors and previously we found that
Platelet-derived growth factor-AB/BB (PDGF-AB/BB) is
one of them [20]. PDGF-AB/BB is required for main-
taining the potential biological events. Since we found
that human tumor cell-derived conditioned media is
Figure 1 Molecular characterization and the effect of TCM on proliferation of 10T1/2 mesenchymal stem cells. A. Identification of
mesenchymal properties of 10T1/2 cells by determining the expression of epithelial or mesenchymal marker proteins using Western blot
analysis. B. A comparative study of a-smooth muscle actin (a-SMA) and desmin expression level in 10T1/2 cells and AOSMC by Western blot
analysis using specific antibodies. The bar graphs represent the quantitative data (mean ± SEM) from three separate experiments. P-values were
determined by unpaired student’s t-test. **p < 0.005 vs 10T1/2 and ***p < 0.001 vs 10T1/2. C. Detection of a-SMA and calponin in 10T1/2 cells
and AOSMC using immunofluorescence. D. Effects of different TCM on 10T1/2 cell proliferation. 1, regular media (RM), 2, MCF-7 cells derived
conditioned media, 3, MDA-MB-231 cells derived conditioned media and 4, Mia-Paca-2 cells derived conditioned media. P-values were
determined by unpaired students’t-test. *p < 0.01 vs RM; #p < 0.05 vs MCF-7-CM.
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into pericytes, we investigated whether PDGF-AB/BB
existed in the TCM, and is required for the mesenchy-
m a lt op e r i c y t et r a n s i t i o n( M P T ) .T od os o ,f i r s t ,w e
neutralized the MDA-MB-231-TCM with polyclonal
rabbit anti-PDGF-BB antibody (500 ng/ml) or rabbit
anti-IgG (negative control) and determined the status of
a-SM-actin using Western blot analysis. The expression
level of the protein in neutralized samples was signifi-
cantly reduced by 2.73-fold as compared to negative
controls (Fig. 3A). Next, we determined the morphologi-
cal alterations as well as a-SM-actin expression using an
immunoefluorescence assay. To examine this, ~60%
confluent 10T1/2 cells were incubated with or without
recombinant PDGF-BB (50ng/ml) at three different
times and cells were fixed with ethanol. The cells
Figure 2 Mesenchymal to pericyte transition (MPT) by different tumor cell-derived conditioned media (TCM). A-B. Representative images
of MPT of 10T1/2 mesenchymal cells grown in regular media or different tumor cell-derived conditioned media for 24 h or 72 h. Cells are
immuno-stained with pericyte-specific marker a-SMA, X200. C. Imuno-Western blots of a-SMA and desmin in 10T1/2 cells grown in different
TCM for 24 h. The bar graphs represent the quantitative analysis from three different experiments. P-values were determined by unpaired
student’s-test. *p < 0.01 vs control (RM).
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morphological studies, which illustrated a differentiation
of fibroblast-like structures into thread-like cells (Fig.
3B). The cells treated for 24 and 72 h were also pro-
cessed for immunofluorescence staining for a-SM-actin
to confirm the morphological and molecular changes,
respectively (Fig. 3C-3F). The level of a-SM-actin pro-
tein was increased in treated cells in a time dependent
fashion. The morphological changes can also be seen in
fluorescence stained cells. Collectively, the studies indi-
cate that the transition from MSC to PC can be accom-
plished by PDGF-BB (Fig. 3B-3G).
Figure 3 Tumor cell secreted PDGF-B is involved in MPT induced by tumor cells. A. Representative immuno-Western blot image illustrates
the effect of PDGF neutralizing antibody on MCF-7-CM-induced a-SMA expression in 10T1/2 cells. B. Representative Giemsa stained Photographs
show that mouse mesenchymal stem cells are converted into pericytes by PDGF recombinant protein after 72 h treatment. C-F. Representative
immunofluorescence images exhibit MPT and a-SMA expression in PDGF-B exposed 10T1/2 cells. G. G. Schematic illustration of mesenchymal
stem cell into pericyte transition.
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Previous studies have manifested a physical interaction of
PDGF-BB with NRP-1 for vascular SMC motility for angio-
genesis [20]. The objective of this work was to evaluate
whether NRP-1 is required for PDGF-BB mediated MPT.
To do so, first, we determined the status of NRP-1 in TCM
exposed and unexposed 10T1/2 cells. NRP-1 expression
was minimally detected in the cell lysate (30 μg) of 10T1/2
cells, but its expression was markedly elevated in MCF-7-
CM-exposed 10T1/2 cells (Fig. 4A). Next, we determined
the impact of the PDGF-BB recombinant protein on MPT
through the detection of tumor blood vessel-pericyte mar-
kers, such as Desmin and a-SMA [15,16]. As expected,
PDGF significantly increased the expression of both mar-
kers in 10T1/2 stem cells (Fig. 4B, lane 2), and these induc-
tions were nullified when cells were pre-exposed to NRP-1
primary antibody (Fig. 4B, lane 3). Collectively, these stu-
dies suggest that a physical interaction of PDGF-BB and
NRP-1 is crucial in PDGF-BB mediated MPT.
TCM is able to recruit/attach of 10T1/2 to a capillary-like
structure in vitro through PDGF-B
In this experiment, we explored whether TCM are able
to increase the recruitment/attachment of transitioned
pericytes with the capillaries formed by the HUVEC. To
do so, a 3 D Matrigel™co-culture was employed. First,
HUVEC were allowed to grow on Matrigel to form a
capillary-like structure in the presence of GFP-tagged-
AOSMC for 18 h and capillary formation was visualized
by fluorescent microscopy. Consistent with previous
work [27,28], this study showed that like in vivo,t h e
AOSMC were able to attach to the capillary-like struc-
tures under in vitro conditions (Fig. 5A). Next, we
evaluated whether TCM-induced mesenchymal-pericyte
transition cells are capable of attaching to the capillary-
like structures in vitro.T ot e s tt h i s ,H U V E Ca n dQ - d o t
labeled 10T1/2 mouse mesenchymal stem cells were
seeded on the matrigel, and their associations were
observed after 20 h when the in vitro capillary-like
structures are formed. The pattern of the tube-like
structure formations in various TCM is different than
regular media. The number of capillary-like structures
was significantly higher in TCM. Moreover, the recruit-
ment and attachment of the newly formed TCM-
induced-pericytes were significantly increased under
TCM as compared to RM (Fig. 5B and 5C). The recruit-
ment and attachment of pericytes vary significantly
within TCM. The effect was more pronounced in MCF-
7 cell-derived conditioned media. Finally, we needed to
determine if PDGF-BB was involved in the TCM-
mediated recruitment event. To do so, HUVEC and Q-
dot labeled 10T1/2 cells were grown on the matrigel
containing RM, MCF-7-CM or PDGF-BB antibody-pre-
exposed-MCF-7-CM for angiogenesis assay. As
expected, MCF-7-CM markedly increased the in vitro
capillary-like structure and the attachment of Q-dot-
labeled cells as compared to RM (Fig. 5B &5C). In con-
trast, PDGF-B antibody-pre-exposed-MCF-7-CM was
unable to either induce capillary-like structure on matri-
gel or induce attachment of labeled cells to the capil-
laries (Figs. 5D and 5E).
TCM is able to recruit/attach of 10T1/2 cell to the newly
formed capillaries in vivo
We investigated whether TCM were able to induce
tumor angiogenesis under in vivo condition. To do so,
Figure 4 NRP-1 is required for PDGF-B mediated induction of a-SMA and desmin expression. A. Representative immuno-Western blot
shows the effect of MCF-7-CM on NRP-1 expression in 10T1/2 cells. 1, RM and 2, MCF-7-CM. *p < 0.001 vs RM. B. Detection of the effect of NRP-
1 antibody on PDGF-B-induced Desmin and a-SMA expression in 10T1/2 cells. The bar graphs represent quantification of the Desmin and a-SMA
of three different experiments, P-values were determined by unpaired students’t-test. *p < 0.001 vs controls; **p < 0.001 vs PDGF treated
samples. Ns, non-significant with controls.
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This assay showed that capillary formation was mark-
edly enhanced on the MCF-7-CM-soaked gel foam as
compared to water or RM soaked gel-foam (Fig. 6A).
Next, we determined whether TCM promotes recruit-
ment and attachment of 10T1/2 cells in TCM-induced
newly formed blood vessels. Like in vitro,T C M
significantly increased the recruitment and attachment
of labeled 10T1/2 cells on newly formed blood vessels
on the gel-foam (Fig. 6B).
Discussion
Differentiation of mural precursor cells to vascular
SMCs/PCs and their recruitment are the fundamental
Figure 5 Recruitment/attachment of vascular SMC and TCM-induced newly formed pericytes from 10T1/2 mesenchymal stem cells on
HUVEC-generated capillary-like structures on Matrigel. A. The photograph showing the attachment of GFP (pZsGreen1C1, GFP-producing
vector) -transfected AOSMC on the newly formed capillaries by HUVEC on 3 D matrigel. B. Differential attachment of Q-dot labeled newly formed
pericytes from 10T1/2 cells on the HUVEC generated capillaries by RM or different tumor cells derived conditioned media on 3 D matrigel. C.
Number of attached Q-dot-labeled newly created pericytes under different tumor cells-conditioned media on capillary-like structures formed by
HUVEC on Matrigel. The data are representative mean ± SEM of ten different capillary-like structures. *p < 0.0001 vs RM; #p < 0.05 vs MDA-MB-CM
or PaCa-CM. D. Upper panel shows the capillary formation in different treatment conditions, and lower panel shows the attachment of Q-dot
labeled 10T1/2 cells on the newly formed capillaries by HUVEC in different treatment conditions on matrigel. RM, Regular Media, MCF-7-CM, MCF-7
cell-derived condition media and MCF-7-CM + PDGF ab
1, MCF-7-CM neutralized by PDGF antibody. Quantification of attachment of Q-dot-labeled
cells using software provided by Nikon fluorescent photo microscope. The represents mean ± SEM of 10 capillaries of each experiment of three
different experiments. P-values were determined by unpaired students’t-test. *p < 0.001 vs RM; **p <0.001 vs MCF-7-CM.
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blood vessels created from nascent vessels [3,20,29].
One aspect that is clear from our previous studies is
that tumor cells can cross-talk with vascular SMCs.
The present study further described an important
issue of whether tumor cells have any roles in PC
biology, most specifically, enhancement of the differ-
entiation of mesenchymal stem cells to pericytes and
subsequent recruitment/attachment of PC for tumor
angiogenesis through a specific molecular networking
circuit.
The initial objective of the present work was to estab-
lish the working hypothesis that the interaction between
tumor cells and mural precursor cells causes the differ-
entiation of precursor cells to PCs, which ultimately
proliferate and recruit to establish a mature and durable
vessel. We found that when 10T1/2 cells, C3 H mouse
embryonic mesenchymal stem cells (C3H/10T1/2) as
characterized by us and others [22] (Fig. 1), were grown
in different breast and pancreatic cancer cell-condi-
tioned media for 2-4 days, the stem cells differentiate
into pericytes with abnormally high expression of
Figure 6 TCM-induced tumor angiogenesis and recruitment/attachment of Q-dot-labeled newly formed pericytes on blood vessels
formed on gel-foam inserted into mice. A. Representative images show the effect of MCF-7-CM on in vivo angiogenesis. Gelfoams, soaked
with water (NC), regular media (RM) or tumor cell-derived media (TCM), were transplanted into the subcutis of mice and angiogenesis was
viewed under the microscope. B. The photograph showing the recruitments of q-dot labeled pericytes on in vivo angiogenesis in three different
conditions [Gelfoam soaked with water (NC), regular media (RM) and tumor-cell-derived condition media (TCM)]. The bar graph represents the
number of Q-dot-labeled blood vessels per field in different treatment conditions. The data represent mean ± SME of three different
experiments. *p of <0.0012 vs negative controls (NC); **p <0.0001 vs RM. C. Diagrammatic illustrations of signaling pathways involved in tumor
cells-generated PDGF-B-induced differentiation of pericytes from mesenchymal stem cells. The studies demonstrate that PDGF-B is responsible
for the differentiation of pericytes from mesenchymal stem cells through PDGF-B-NRP-1 signaling pathway.
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identical to the pericytes on tumor vessels [15,16]. Thus,
we can anticipate that tumor cells have the capability to
generate specific signals for mesenchymal to pericyte
transitions.
Our next goal was to identified the signaling networks
involved in tumor cell-induced MPT. The pericytes can
originate from various cell lineages [14,30] and com-
monly come from mesenchymal stem cells [14,31].
There are two important molecular signaling pathways
that are involved in the development of pericytes [32],
TGF-b and PDGF-B signaling pathways [14,33,34]. Pre-
vious studies have shown that embryonic stem cells are
able to differentiate into endothelial cells if they are
exposed to VEGF, while they can be differentiated into
pericytes in presence of PDGF-B [35-37]. In our in vitro
model, we found that tumor cell-secreted PDGF-B plays
a critical role in MPT (Figs.3 and 4). Most importantly,
we found that the tumor cell-secreted PDGF-B-induced
MPT event is mediated through NRP-1 (neuroplin-1),
which is a co-receptor for semaphorins with key roles in
axon guidance, a docking receptor for VEGF165 [38,39]
and exhibits a physical interaction with PDGF-B in vas-
cular SMC to enhance their migration [20,38].
One of the key steps of the termination of angiogen-
esis is the incorporation of pericytes/vascular SMCs into
the newly formed vessels [13,40,41]. We explored if
tumor cells can enhance the recruitment and incorpora-
tion of pericytes into the newly formed endothelial
tubes under in vitro and in vivo setups. The studies
showed that in addition to induction of MPT, the tumor
cell-generated signals including PDGF-B are able to
increase the recruitment and attachment of newly differ-
entiated pericytes into the blood vessels (Figs. 5 and 6).
However, the impact of different tumor cell lines that
cause pericytes to attach to bl o o dv e s s e l si sd i f f e r e n t .
Less aggressive cell lines, such as MCF-7 non-invasive
breast tumor cell-generated CM caused more abundant
recruitment/attachment of pericytes to the blood vessels
as compared to aggressive cell lines (i.e., MDA-MB-231
and MIA-PaCa-2)-generated CM (Fig. 5). Recent studies
reveal that pericytes limit metastatic spread in pancrea-
tic b-islet cell tumorigenesis in PDGFRb
ret/ret mice [42]
and in patients with colorectal cancer [43]. In agreement
with these findings, less abundant recruitment of peri-
cytes by aggressive tumor cell-CM may correlate with
metastatic spread of these cells. Because MCF-7, MDA-
MB-231 and MIA-PaCa-2 cells highly expressed PDGF-
B but the CM of later two tumor cell lines were unable
to facilitate pericytes to attach more abundantly to the
capillary-like structures as compared to MCF-7-CM,
these studies indicate that some additional factor(s) is
essential for proper adhesion of pericytes to the vessels,
which is either missing or inhibited by aggressive cancer
cells for metastatic spread. Further studies are war-
ranted. Finally, the studies also show that PDGF-B sig-
naling not only influences MPT and recruitment of
pericytes but also affects in vitro capillary stability by
unknown mechanisms (Fig. 5D, last panel).
Conclusions
In conclusion, this work, as depicted in Fig. 6C, provides
direct evidence that tumor cells enhance the mesenchy-
mal to pericyte transition event for the recruitment and
adhesion of pericytes on newly formed blood vessels to
terminate the tumor angiogenesis process. These multi-
step events are apparently mediated by tumor cell-
secreted PDGF-B signaling molecule. NRP-1 may play a
critical role in this event. We anticipate a direct link
between the disparity in recruitment of pericytes by var-
ious tumor cells and their metastatic potency. In sup-
port of this study, targeting tumor cell-secreted PDGF-B
or NRP-1 in pericytes by inhibitors may efficiently
diminish the tumor angiogenesis, tumor growth and
metastatic spread.
Materials and methods
Cell culture
The mouse embryonic mesenchymal stem cells, C3H/
10T1/2, non-invasive breast tumor cells MCF-7, T-47 D
and ZR-75-1, invasive breast cancer cells MDA-MB-
231and invasive pancreatic carcinoma cells MIA-PaCa-2,
were obtained from American Type Culture Collection
(ATCC, Manassas, VA) and grown in Dulbecco’sm o d i -
fied Eagle’s medium (DMEM, Sigma Chemical Co, St.
Louis, MO) supplemented with 10% fetal calf serum and
antibiotics, in a humidified incubator at 37°C in an
atmosphere containing 5% CO2 and 95% O2. Human
aortic smooth muscle cells (AOSMC) and HUVEC
(human umbilical vein endothelial cells) were purchased
from Cambrex and grown in smooth muscle cells basal
media (SmBM) with various growth factors (SmGM-2, i.
e . ,i n s u l i n ,F G F ,E G Fa n d2 %s e r u m )a n dE G M - 2b u l l e t
kit (EBM-2, the basal medium supplemented with
growth factors and 5% serum) respectively.
Animals
FVB/N mice (6-8 weeks of age), purchased from Taconic
( H u d s o n ,N Y )w e r eh o u s e di na u t o c l a v e dc a g e sf i t t e d
with high efficiency filter-tops and with autoclaved bed-
ding. The animals were fed irradiated Purina chow. The
room was kept at 25°C with a 12-h light-dark cycle. The
animal studies were carried out as per the guidelines
established in the G u i d ef o rt h eC a r ea n dU s eo f
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Human Resources (NIH 1985) and VA Animal Care
facilities.
Reagents
B-forms of PDGF protein and Giemsa were purchased
from Sigma Chemical Co. Polyclonal rabbit anti-PDGF-
BB, mouse monoclonal alpha smooth muscle-actin and
Desmin antibodies were purchased from abCam (Cam-
bridge, MA). Goat-anti mouse E-cadherin and b-Catenin
and Goat-anti mouse Cytokeratin-19 and Vimentin were
obtained from BD Transduction and Labvision (Neo-
marker) respectively. A Qtracker cell labeling kit was
purchased from Invitrogen (Molecular Probes, Eugene,
Oregon). Matrigel was purchased from BD Biosciences.
Preparation of tumor cell-Conditioned Media (TCM)
The procedure of preparation was the same as pre-
viously described [20]. Br i e f l y ,M C F - 7 ,M D A - M B - 2 3 1
and MIA-PaCa-2 cells were grown in DMEM media for
24 hours and collected. They were centrifuged for 10
min at 2000 rpm at 4°C to remove the cells or cell deb-
ris. After, centrifugation, media were collected and used
for the experiments.
Cell Count
~70% confluent 10T1/2 cells were incubated with differ-
ent tumor cell-derived condition media for 24 hours.
Cells were trypsinized after 24 hours and stained with
trypan blue for the count in Cellometer Auto T4 (Nex-
celom Bioscience, Lawrence, MA 01843).
Immunofluorescence
Briefly, ~60% 10T1/2 confluent cells that were grown in a
one-well slide chamber were incubated with or without
PDGF-BB (Platelet-derived growth factor-BB) or different
tumor conditioned media (MCF-7, MDA-MB-231 and
MIA-PaCa-2) for 24 and 72 hours at 37°C and fixed with
methanol. The slides were then permeabilized with Tri-
ton-X-100 and incubated with blocking solution (Histos-
tain kit, Zymed Laboratories, CA) for 10 mins at room
temperature, and cells were reacted with mouse mono-
clonal alpha smooth muscle actin antibody overnight at
4°C. After being washed with PBS, the cells were incu-
bated with goat anti-mouse IgG fluorescent conjugated
secondary antibody for an hour at room temperature
(1:1000 dilutions, Alexa Fluor 594, Molecular Probes).
Finally, the washed cells were mounted in PBS-glycerin
and examined under a fluorescent microscope.
Western blot analysis
The Western blot analysis was performed in cell lysates
treated with different cells derived conditioned medium
according to the method described previously [20]. Cell
lysates were obtained by adding lysis buffer containing
50 mM Tris-Cl, pH-8.0, 0.1% SDS, 150 mM NaCl, 1%
Nonidet P-40 and protease inhibitor cocktail including 1
μg/ml of Aprotinin, 1 μg/ml leupepsin and 1 mM PMSF
and centrifuged at 4°C. The supernatants were collected
and protein concentrations were measured with coo-
massie blue reagent assay (Bio-Rad, Richmond, CA).
Equal amounts of protein (10 μg) were subjected to 7.5
- 10% SDS-PAGE and blotted onto a nitrocellulose
membrane. Membranes were incubated with specific
antibodies anti-mouse monoclonal smooth muscle actin
overnight and HRP-conjugated secondary antibodies
were incubated for 30 min at room temperature. Signals
were detected with Super Signal Ultra Chemilumines-
cent substrate (Pierce, Rockford, IL) by using ID Image
Analysis software Version 3.6 (Eastman Kodak Com-
pany, Rochester, NY).
Neutralization assay
To determine the identity of the growth factor in the
tumor cell-derived condition media that were mediating
the conversion of stem cells into PCs, the media, condi-
tioned by semi-confluent MCF-7, MDA-MB-231 and
MIA-PaCa-2 cells, were preincubated overnight at 4°C
with different concentrations (i.e., 200 and 500 ng/ml)
of a neutralizing polyclonal antibody against PDGF-BB.
The semi confluent mesenchymal stem cells, 10T1/2,
were then incubated with regular medium (as a control),
tumor cell-derived conditioned media, neutralizing
media [tumor cell-derived condition media (CM) neu-
tralized with anti-PDGF-BB antibody and rabbit polyclo-
nal IgG (as a negative control)] for 24 hours at 37°C.
After that, cell lysates were collected to perform the
Western blot analysis for the detection of the expression
level of anti-smooth muscle actin.
In vitro angiogenesis and Binding assay
Approximately 80% confluent 10T1/2 cells were labeled
with Qtracker cell labeling kit (highly fluorescent Q-dot
nanocrystals) obtained from Invitrogen (Molecular
Probes). For 3 D cultures, which has been described ear-
lier [44], Matrigel (150 μl) was polymerized in an 8-well
chambered slide. After polymerization, endothelial cell-
specific media or tumor cell-generated conditioned
media were added. HUVEC and labeled 10T1/2 cells
(10,000 cells/well) were seeded into each well and incu-
bated for approximately 20 h which determined the
binding efficiency of 10T1/2 cells with capillary-like
structure generated by HUVEC in regular media or dif-
ferent tumor cell-derived condition media. Quantifica-
tion of the number of capillary-like structures and
attached Q-dots were carried out using the NIS Ele-
ments software program attached with the Nikon photo-
graphic fluorescence microscope.
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The Gelfoam-implantation angiogenesis assay was per-
formed according to the previous method [45,46]. Briefly,
three sets of FVB/N mice (6-8 weeks old; four in each
set) were anesthetized immediately before implantation
of Gelfoam (Gelfoam®, Pharmacia & Upjohn Company,
NY, USA). Gelfoam (8 × 8 mm), presoaked with auto-
claved water, regular media or TCM, was transplanted
subcutaneously in mice. The transplanted mice were
maintained for 5-6 days. In the mean time, Q-dot labeled
10T1/2 cells were cultured in regular media or TCM.
After a maintenance period, labeled 10T1/2 cells
(2 × 10
5) were injected subcutaneously near implanted
Gelfoam according to the experimental set-up. The
implanted Gelfoam was taken out carefully after 2 days,
and the angiogenesis was detected and quantified using
an inverted fluorescence microscope. The protocol has
been depicted in Additional file 1: Fig. S1.
Statistical Analysis
All experiments were performed in triplicate for each of
the observations. Each of the data represents the mean
± SE from the three separate experiments. Statistical
analysis was performed between the two groups of data
by an unpaired Student’s t-test. A P-value less than 0.05
were considered as statistically significant.
Additional material
Additional file 1: Figure S1 - Diagrammatic illustration of Gelfoam-
implantation angiogenesis assay. FVB/N mice (6-8 weeks old; four in
each set) were anesthetized with Ketamine HCL (100 mg/ml/kg) and
Xylazine (20 mg/ml/kg) immediately before implantation of Gelfoam
(Gelfoam®, Pharmacia & Upjohn Company, NY, USA). Gelfoam was cut
into small Pieces (8 × 8 mm), presoaked with autoclaved water, regular
media or Tumor cell-conditioned media (TCM). Presoaked Gelfoam was
transplanted subcutaneously on left or right flank of mice. The
transplanted mice were maintained for 5-6 days. In the mean time, Q-
dot labeled 10T1/2 cells were cultured in regular media or TCM. After
maintenance period, labeled 10T1/2 cells (2 × 10
5) were injected
subcutaneously near implanted Gelfoam according to the experimental
set-up. The implanted Gelfoam was taken out carefully after 2 days and
the angiogenesis was detected and quantified using inverted
fluorescence microscope.
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